查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067601

抗生素抗藥性市場規模、佔有率和趨勢分析報告：按疾病、病原體、藥物類別、作用機制、分銷管道和細分市場預測（2026-2033 年）

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease, By Pathogen, By Drug Class, By Mechanism Of Action, By Distribution Channel, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

抗菌素抗藥性市場概述

全球抗生素抗藥性市場預計在 2025 年達到 96.5 億美元，預計從 2026 年的 101.5 億美元成長到 2033 年的 142.6 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 4.98%。

到 2025 年，北美抗生素抗藥性市場將佔全球市場佔有率的 36.47%，成為最大的市場佔有率。

大腸桿菌、肺炎克雷伯菌、金黃色葡萄球菌和鮑曼分枝桿菌等病原體的抗藥性日益增強，給全球醫療保健系統帶來了巨大壓力。醫院感染、血流感染疾病、尿道感染和呼吸道感染疾病的發生率不斷上升，促使人們迫切需要先進的抗菌療法和快速診斷技術。此外，抗藥性感染疾病導致的死亡率上升以及加護病房日益沉重的臨床負擔，也進一步推動了對新型抗菌藥物的需求。

抗菌藥物抗藥性產業的成長也得益於對抗菌藥物創新、非傳統抗菌療法和精準診斷平台的投資增加。製藥公司、生物技術公司和學術機構正日益專注於開發新一代抗生素、噬菌體療法、基於微生物組的治療方法、單株抗體以及人工智慧驅動的藥物發現平台，以對抗抗藥性病原體。例如，世界衛生組織（世衛組織）在2025年10月指出，儘管創新工作不斷推進，但全球抗菌藥物研發管線仍不足，並強調迫切需要對藥物進行新的化學分類，以及改進口服治療方法方案。此外，人工智慧在抗菌藥物研發中的日益普及正在加速化合物篩檢和病原體標靶治療方法的開發。對從事抗菌藥物研發的中小型生物技術公司投入的資金增加，進一步促進了技術進步，並增強了其長期成長潛力。

戰略聯盟、國際資助舉措和官民合作關係正日益重塑抗菌素抗藥性市場的競爭格局。各國政府、監管機構和醫療衛生組織正在加強全球合作，以改善抗生素的可近性、改善監測系統和抗菌素研究基礎設施。日益重視「同一健康」舉措（該計劃整合了人類、動物和環境健康）也有助於制定更廣泛的抗菌素抗藥性管理策略。此外，增加對診斷、監測項目以及針對世界衛生組織指定的優先病原體的抗菌藥物研發的投資，也推動了市場成長。北美、歐洲和亞太地區的衛生部門正在增加對抗菌素創新計畫的資助，以應對抗藥性感染疾病日益嚴重的社會經濟負擔。這些努力有望加速新治療方法的商業化，並提高全球抗菌素抗藥性治療市場的長期永續性。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：抗生素抗藥性市場：變數、趨勢和範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：抗生素抗藥性市場：疾病特異性商業分析

  • 按疾病分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按疾病分類，2021-2033 年
  • 複雜性尿道感染(cUTI)
  • CDI（困難梭狀桿菌感染疾病）
  • 急性細菌性胃及結構感染疾病（ABSSSI）
  • 本院獲得性細菌性肺炎（HABP）
  • 社區型肺炎 (CABP)
  • cIAI（複雜性腹腔內感染疾病）
  • 血流感染疾病（BSI）

第5章：抗生素抗藥性市場：按病原體分類的商業分析

  • 按病原體分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按病原體分類，2021-2033 年
  • 大腸桿菌
  • K. pneumoniae
  • P. aeruginosa
  • S. aureus
  • A. baumannii
  • S. pneumoniae
  • H. influenzae
  • CDI
  • E. faecium

第6章：抗生素抗藥性市場：按藥物類別分類的業務分析

  • 按藥物類別分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按藥物類別分類，2021-2033 年
  • Oxazolidinone系列
  • 醣肽
  • 四環黴素
  • 聯合治療
  • 頭孢菌素
  • 其他

第7章：抗菌藥物抗藥性市場：基於作用機制的商業分析

  • 按作用機制分類的市場佔有率（2025 年和 2033 年）
  • 依作用機制分類的市場規模、預測與趨勢分析（2021年至2033年）
  • 蛋白質合成抑制劑
  • 細胞壁合成抑制劑
  • RNA合成抑制劑
  • DNA合成抑制劑
  • 其他

第8章：抗生素抗藥性市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 抗生素抗藥性市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第10章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Melinta Therapeutics
    • Basilea Pharmaceutica Ltd.
    • Tetraphase Pharmaceuticals
    • Theravance Biopharma
    • WOCKHARDT
    • Paratek Pharmaceuticals, Inc.
    • Seres Therapeutics
    • ACHAOGEN, INC.
    • Entasis Therapeutics
    • AbbVie
Product Code: GVR-2-68038-663-9

Antibiotic Resistance Market Summary

The global antibiotic resistance market size was estimated at USD 9.65 billion in 2025 and is projected to grow from USD 10.15 billion in 2026 to USD 14.26 billion by 2033, at a CAGR of 4.98% from 2026 to 2033. The North America antibiotic resistance market held the largest global share of 36.47% in 2025.

Increasing resistance among pathogens such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Acinetobacter baumannii is creating significant pressure on healthcare systems worldwide. The growing incidence of hospital-acquired, bloodstream, urinary tract, and respiratory infections is accelerating the need for advanced antibacterial therapies and rapid diagnostic technologies. Additionally, rising mortality rates from resistant infections and the expanding clinical burden in intensive care settings are driving demand for novel antimicrobial agents.

The growth of the antibiotic resistance industry is also driven by increasing investments in antibiotic innovation, non-traditional antibacterial therapies, and precision diagnostic platforms. Pharmaceutical companies, biotechnology firms, and academic institutions are increasingly focusing on the development of next-generation antibiotics, bacteriophage therapies, microbiome-based therapeutics, monoclonal antibodies, and AI-assisted drug discovery platforms to combat resistant pathogens. For instance, in October 2025, the World Health Organization highlighted that the global antibacterial pipeline remains insufficient despite ongoing innovation efforts, emphasizing the urgent requirement for new chemical classes and improved oral treatment options. Furthermore, the growing integration of artificial intelligence into antimicrobial drug discovery is accelerating compound screening and the development of pathogen-targeted therapies. Rising funding support for small and mid-sized biotechnology companies engaged in antibacterial R&D is further contributing to technological advancements and strengthening long-term market growth opportunities.

Strategic collaborations, international funding initiatives, and public-private partnerships are increasingly shaping the competitive landscape of the antibiotic resistance market. Governments, regulatory agencies, and healthcare organizations are strengthening global coordination to improve antibiotic accessibility, surveillance systems, and antimicrobial research infrastructure. The growing focus on One Health initiatives integrating human, animal, and environmental health is also contributing to broader antimicrobial resistance management strategies. Additionally, increased investments in diagnostics, surveillance programs, and antibacterial development targeting WHO priority pathogens are supporting market growth. Healthcare authorities across North America, Europe, and Asia Pacific are expanding funding for antimicrobial innovation programs to address the rising socioeconomic burden of resistant infections. These initiatives are expected to accelerate the commercialization of novel therapies and enhance long-term market sustainability in the global antibiotic resistance treatment landscape.

Global Antibiotic Resistance Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antibiotic resistance market report based on disease, pathogen, mechanism of action, drug class, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • cUTI (Complicated Urinary Tract Infections)
  • CDI (Clostridioides difficile Infection)
  • ABSSSI (Acute bacterial skin and skin structure infections)
  • HABP (Hospital-acquired bacterial pneumonia)
  • CABP
  • cIAI
  • BSI
  • Pathogen Outlook (Revenue, USD Million, 2021 - 2033)
  • E. coli
  • klebsiella pneumoniae
  • P. aeruginosa
  • S. aureus
  • A. baumannii
  • Strep. pneumoniae
  • H. influenzae
  • CDI
  • Enterococcus faecium
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Combination therapies
  • Cephalosporins
  • Others
  • Mechanism of Action Outlook (Revenue, USD Million, 2021 - 2033)
  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Pathogen
    • 1.2.3. Drug Class
    • 1.2.4. Mechanism of Action
    • 1.2.5. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antibiotic Resistance Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Antibiotic Resistance Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2025 & 2033
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 4.4. cUTI (Complicated Urinary Tract Infections)
    • 4.4.1. cUTI (Complicated Urinary Tract Infections) Market, 2021 - 2033 (USD Million)
  • 4.5. CDI (Clostridioides difficile Infection)
    • 4.5.1. CDI (Clostridioides difficile Infection) Market, 2021 - 2033 (USD Million)
  • 4.6. ABSSSI (Acute bacterial skin and skin structure infections)
    • 4.6.1. ABSSSI (Acute bacterial skin and skin structure infections) Market, 2021 - 2033 (USD Million)
  • 4.7. HABP (Hospital-acquired bacterial pneumonia)
    • 4.7.1. HABP (Hospital-acquired bacterial pneumonia) Market, 2021 - 2033 (USD Million)
  • 4.8. CABP (Community-acquired pneumonia)
    • 4.8.1. CABP (Community-acquired pneumonia) Market, 2021 - 2033 (USD Million)
  • 4.9. cIAI (Complicated intra-abdominal infection)
    • 4.9.1. cIAI (Complicated intra-abdominal infection) Market, 2021 - 2033 (USD Million)
  • 4.10. BSI (Bloodstream infection)
    • 4.10.1. BSI (Bloodstream infection) Market, 2021 - 2033 (USD Million)

Chapter 5. Antibiotic Resistance Market: Pathogen Business Analysis

  • 5.1. Pathogen Market Share, 2025 & 2033
  • 5.2. Pathogen Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Pathogen, 2021 to 2033 (USD Million)
  • 5.4. E. coli
    • 5.4.1. E. coli Market, 2021 - 2033 (USD Million)
  • 5.5. K. pneumoniae
    • 5.5.1. K. pneumoniae Market, 2021 - 2033 (USD Million)
  • 5.6. P. aeruginosa
    • 5.6.1. P. aeruginosa Market, 2021 - 2033 (USD Million)
  • 5.7. S. aureus
    • 5.7.1. S. aureus Market, 2021 - 2033 (USD Million)
  • 5.8. A. baumannii
    • 5.8.1. A. baumannii Market, 2021 - 2033 (USD Million)
  • 5.9. S. pneumoniae
    • 5.9.1. S. pneumoniae Market, 2021 - 2033 (USD Million)
  • 5.10. H. influenzae
    • 5.10.1. H. influenzae Market, 2021 - 2033 (USD Million)
  • 5.11. CDI
    • 5.11.1. CDI Market, 2021 - 2033 (USD Million)
  • 5.12. E. faecium
    • 5.12.1. E. faecium Market, 2021 - 2033 (USD Million)

Chapter 6. Antibiotic Resistance Market: Drug Class Business Analysis

  • 6.1. Drug Class Market Share, 2025 & 2033
  • 6.2. Drug Class Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 6.4. Oxazolidinones
    • 6.4.1. Oxazolidinones Market, 2021 - 2033 (USD Million)
  • 6.5. Lipoglycopeptides
    • 6.5.1. Lipoglycopeptides Market, 2021 - 2033 (USD Million)
  • 6.6. Tetracyclines
    • 6.6.1. Tetracyclines Market, 2021 - 2033 (USD Million)
  • 6.7. Combination therapies
    • 6.7.1. Combination Therapies Market, 2021 - 2033 (USD Million)
  • 6.8. Cephalosporins
    • 6.8.1. Cephalosporins Market, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Antibiotic Resistance Market: Mechanism of Action Business Analysis

  • 7.1. Mechanism of Action Market Share, 2025 & 2033
  • 7.2. Mechanism of Action Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Mechanism of Action, 2021 to 2033 (USD Million)
  • 7.4. Protein Synthesis Inhibitors
    • 7.4.1. Protein Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.5. Cell Wall Synthesis Inhibitors
    • 7.5.1. Cell Wall Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.6. RNA Synthesis Inhibitors
    • 7.6.1. RNA Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.7. DNA Synthesis Inhibitors
    • 7.7.1. DNA Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.8. Others
    • 7.8.1. Others Synthesis Inhibitors Market, 2021 - 2033 (USD Million)

Chapter 8. Antibiotic Resistance Market: Distribution Channel Business Analysis

  • 8.1. Distribution Channel Market Share, 2025 & 2033
  • 8.2. Distribution Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 8.5. Retail Pharmacies
    • 8.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 9. Antibiotic Resistance Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2025 & 2033
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4. North America
    • 9.4.1. North America Antibiotic Resistance Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Target Disease Prevalence
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Reimbursement Framework
      • 9.4.2.5. U.S. Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Reimbursement Framework
      • 9.4.3.5. Canada Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Reimbursement Framework
      • 9.4.4.5. Mexico Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Target Disease Prevalence
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Reimbursement Framework
      • 9.5.2.5. UK Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Reimbursement Framework
      • 9.5.3.5. Germany Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Target Disease Prevalence
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Reimbursement Framework
      • 9.5.4.5. France Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Target Disease Prevalence
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. Reimbursement Framework
      • 9.5.5.5. Italy Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Target Disease Prevalence
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Reimbursement Framework
      • 9.5.6.5. Spain Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Target Disease Prevalence
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. Reimbursement Framework
      • 9.5.7.5. Denmark Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Target Disease Prevalence
      • 9.5.8.3. Regulatory Framework
      • 9.5.8.4. Reimbursement Framework
      • 9.5.8.5. Sweden Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Target Disease Prevalence
      • 9.5.9.3. Regulatory Framework
      • 9.5.9.4. Reimbursement Framework
      • 9.5.9.5. Norway Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Target Disease Prevalence
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Reimbursement Framework
      • 9.6.2.5. Japan Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Reimbursement Framework
      • 9.6.3.5. China Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Reimbursement Framework
      • 9.6.4.5. India Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Reimbursement Framework
      • 9.6.5.5. Australia Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Target Disease Prevalence
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. Reimbursement Framework
      • 9.6.6.5. South Korea Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Target Disease Prevalence
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Reimbursement Framework
      • 9.6.7.5. Thailand Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Target Disease Prevalence
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. Reimbursement Framework
      • 9.7.2.5. Brazil Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Target Disease Prevalence
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Reimbursement Framework
      • 9.7.3.5. Argentina Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Middle East and Africa
    • 9.8.1. Middle East and Africa Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Target Disease Prevalence
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. Reimbursement Framework
      • 9.8.2.5. South Africa Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Target Disease Prevalence
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Reimbursement Framework
      • 9.8.3.5. Saudi Arabia Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Target Disease Prevalence
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. Reimbursement Framework
      • 9.8.4.5. UAE Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Target Disease Prevalence
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Reimbursement Framework
      • 9.8.5.5. Kuwait Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Melinta Therapeutics
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. Basilea Pharmaceutica Ltd.
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Tetraphase Pharmaceuticals
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Theravance Biopharma
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. WOCKHARDT
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Paratek Pharmaceuticals, Inc.
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.7. Seres Therapeutics
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial Performance
      • 10.5.7.3. Product Benchmarking
      • 10.5.7.4. Strategic Initiatives
    • 10.5.8. ACHAOGEN, INC.
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Product Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Entasis Therapeutics
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Product Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. AbbVie
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global antibiotic resistance market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 5. Global antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 6. Global antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 7. Global antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 8. Global antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. North America antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 10. North America antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 11. North America antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 12. North America antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 13. North America antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 14. North America antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. U.S. antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 16. U.S. antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 17. U.S. antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 18. U.S. antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 19. U.S. antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Canada antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 21. Canada antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 22. Canada antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 23. Canada antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 24. Canada antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25. Mexico antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 26. Mexico antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 27. Mexico antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 28. Mexico antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 29. Mexico antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Europe antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 31. Europe antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 32. Europe antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 33. Europe antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 34. Europe antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 35. Europe antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36. UK antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 37. UK antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 38. UK antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 39. UK antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 40. UK antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. Germany antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 42. Germany antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 43. Germany antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 44. Germany antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 45. Germany antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46. France antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 47. France antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 48. France antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 49. France antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 50. France antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 51. Italy antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 52. Italy antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 53. Italy antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 54. Italy antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 55. Italy antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Spain antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 57. Spain antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 58. Spain antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 59. Spain antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 60. Spain antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Norway antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 62. Norway antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 63. Norway antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 64. Norway antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 65. Norway antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 66. Denmark antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 67. Denmark antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 68. Denmark antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 69. Denmark antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 70. Denmark antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71. Sweden antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 72. Sweden antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 73. Sweden antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 74. Sweden antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 75. Sweden antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 76. Asia Pacific antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 77. Asia Pacific antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 78. Asia Pacific antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 79. Asia Pacific antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 80. Asia Pacific antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 81. Asia Pacific antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 82. Japan antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 83. Japan antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 84. Japan antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 85. Japan antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 86. Japan antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87. China antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 88. China antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 89. China antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 90. China antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 91. China antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 92. India antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 93. India antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 94. India antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 95. India antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 96. India antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 97. Australia antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 98. Australia antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 99. Australia antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 100. Australia antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 101. Australia antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 102. South Korea antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 103. South Korea antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 104. South Korea antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 105. South Korea antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 106. South Korea antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 107. Thailand antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 108. Thailand antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 109. Thailand antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 110. Thailand antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 111. Thailand antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 112. Latin America antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 113. Latin America antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 114. Latin America antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 115. Latin America antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 116. Latin America antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 117. Latin America antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 118. Brazil antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 119. Brazil antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 120. Brazil antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 121. Brazil antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 122. Brazil antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 123. Argentina antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 124. Argentina antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 125. Argentina antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 126. Argentina antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 127. Argentina antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 128. Middle East & Africa antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 129. Middle East & Africa antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 130. Middle East & Africa antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 131. Middle East & Africa antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 132. Middle East & Africa antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 133. Middle East & Africa antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 134. South Africa antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 135. South Africa antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 136. South Africa antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 137. South Africa antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 138. South Africa antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 139. Saudi Arabia antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 140. Saudi Arabia antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 141. Saudi Arabia antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 142. Saudi Arabia antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 143. Saudi Arabia antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 144. UAE antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 145. UAE antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 146. UAE antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 147. UAE antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 148. UAE antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 149. Kuwait antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 150. Kuwait antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 151. Kuwait antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 152. Kuwait antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 153. Kuwait antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Antibiotic resistance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Antibiotic resistance market dynamics
  • Fig. 11 Antibiotic resistance market: Porter's five forces analysis
  • Fig. 12 Antibiotic resistance market: PESTLE analysis
  • Fig. 13 Disease market, 2021 - 2033 (USD Million)
  • Fig. 14 cUTI (complicated urinary tract infections) market, 2021 - 2033 (USD Million)
  • Fig. 15 CDI (Clostridioides difficile Infection) market, 2021 - 2033 (USD Million)
  • Fig. 16 ABSSSI (Acute Bacterial Skin and Skin Structure Infections) market, 2021 - 2033 (USD Million)
  • Fig. 17 HABP (hospital-acquired bacterial pneumonia) market, 2021 - 2033 (USD Million)
  • Fig. 18 CABP (community-acquired pneumonia) market, 2021 - 2033 (USD Million)
  • Fig. 19 cIAI (complicated intra-abdominal infection) market, 2021 - 2033 (USD Million)
  • Fig. 20 BSI (bloodstream infection) market, 2021 - 2033 (USD Million)
  • Fig. 21 Pathogens market, 2021 - 2033 (USD Million)
  • Fig. 22 E. coli market, 2021 - 2033 (USD Million)
  • Fig. 23 K. pneumoniae market, 2021 - 2033 (USD Million)
  • Fig. 24 P. aeruginosa market, 2021 - 2033 (USD Million)
  • Fig. 25 S. aureus market, 2021 - 2033 (USD Million)
  • Fig. 26 A. baumannii market, 2021 - 2033 (USD Million)
  • Fig. 27 S. pneumoniae market, 2021 - 2033 (USD Million)
  • Fig. 28 H. influenzae market, 2021 - 2033 (USD Million)
  • Fig. 29 CDI market, 2021 - 2033 (USD Million)
  • Fig. 30 E. faecium market, 2021 - 2033 (USD Million)
  • Fig. 31 Drug class market, 2021 - 2033 (USD Million)
  • Fig. 32 Oxazolidinones market, 2021 - 2033 (USD Million)
  • Fig. 33 Lipoglycopeptides market, 2021 - 2033 (USD Million)
  • Fig. 34 Tetracyclines market, 2021 - 2033 (USD Million)
  • Fig. 35 Combination therapies market, 2021 - 2033 (USD Million)
  • Fig. 36 Cephalosporins market, 2021 - 2033 (USD Million)
  • Fig. 37 Others market, 2021 - 2033 (USD Million)
  • Fig. 38 Mechanism of action market, 2021 - 2033 (USD Million)
  • Fig. 39 Protein synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 40 Cell wall synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 41 RNA synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 42 DNA synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 43 Others market, 2021 - 2033 (USD Million)
  • Fig. 44 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 45 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 46 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 47 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 48 Antibiotic resistance market revenue, by region
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 North America Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 51 U.S. country dynamics
  • Fig. 52 U.S. Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 53 Canada country dynamics
  • Fig. 54 Canada Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 55 Mexico country dynamics
  • Fig. 56 Mexico Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 57 Europe Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 58 UK country dynamics
  • Fig. 59 UK Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 60 Germany country dynamics
  • Fig. 61 Germany Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 62 France country dynamics
  • Fig. 63 France Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 64 Italy country dynamics
  • Fig. 65 Italy Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 66 Spain country dynamics
  • Fig. 67 Spain Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 68 Norway country dynamics
  • Fig. 69 Norway Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 70 Sweden country dynamics
  • Fig. 71 Sweden Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 72 Denmark country dynamics
  • Fig. 73 Denmark Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 74 Asia Pacific Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 75 Japan country dynamics
  • Fig. 76 Japan Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 77 China country dynamics
  • Fig. 78 China Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 79 India country dynamics
  • Fig. 80 India Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 81 Australia country dynamics
  • Fig. 82 Australia Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 83 South Korea country dynamics
  • Fig. 84 South Korea Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 85 Thailand country dynamics
  • Fig. 86 Thailand Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 87 Latin America Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 88 Brazil country dynamics
  • Fig. 89 Brazil Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 90 Argentina country dynamics
  • Fig. 91 Argentina Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 92 MEA Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 93 South Africa country dynamics
  • Fig. 94 South Africa Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 95 Saudi Arabia country dynamics
  • Fig. 96 Saudi Arabia Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 97 UAE country dynamics
  • Fig. 98 UAE Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 99 Kuwait country dynamics
  • Fig. 100 Kuwait Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 101 Company categorization
  • Fig. 102 Company market position analysis
  • Fig. 103 Strategic framework